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Abstract
Hepatitis C Virus E1E2 heterodimers are components of the viral spike. Although there is a general agreement on the
necessity of the co-expression of both E1 and E2 on a single coding unit for their productive folding and assembly, in a
previous study using an in vitro system we obtained strong indications that E1 can achieve folding in absence of E2. Here,
we have studied the folding pathway of unescorted E1 from stably expressing CHO cells, compared to the folding observed
in presence of the E2 protein. A DTT-resistant conformation is achieved by E1 in both situations, consistent with the
presence of an E2-independent oxidative pathway. However, while the E1E2 heterodimer is stable inside cells, E1 expressed
alone is degraded within a few hours. On the other hand, the oxidation and stability of individually expressed E2 subunits is
dependent on E1 co-expression. These data are consistent with E1 and E2 assisting each other for correct folding via
different mechanisms: E2 assists E1 by stabilizing a semi-native conformation meanwhile E1 drives E2 towards a productive
folding pathway.
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Introduction
The HepatitisC virus(HCV)istheetiologicagent ofanimportant
global disease causing chronic liver infection, which can lead to
cirrhosis and hepatocelllular carcinoma [1]. HCV shares common
features with pestiviruses and flaviviruses, such as being enveloped
and consisting of single stranded positive RNA genome coding for a
single open reading frame (ORF), but has been classified within a
separate genus of the flaviviridae family [2]. The mature HCV viral
proteins are generated via co- and post-translational cleavages that
are dependent on the concerted action of host and viral proteases.
The 59 end of the genome encodes for the structural proteins: Core,
the unique proteic component of the viral nucleocapsid, and two
glycoproteins, E1 and E2, responsible for viral attachment and entry
into host cells [3,4,5]. Intracellularly expressed E1and E2 lead to the
formation ofnon-covalent associated heterodimericcomplexes.E2is
incompletely cleaved from the adjacent p7 protein generating a
detectable E2p7 product whose role in viral particle formation, if
any, is still unknown. The remaining two thirds of the genome
encodes the non-structural (NS) proteins NS2, NS3, NS4A, NS4B,
NS5A and NS5B [2]. Although NS2 is dispensable for replication, it
has been classified as a non-structural protein since it has not been
found to be assembled into virus particles, even though it is involved
in viral assembly [6,7].
Establishment of a functional non-covalent E1E2 heterodimer is
a crucial step for viral particle formation. During translation of the
polyprotein, appropriate signal sequences target the two glyco-
proteins to the endoplasmic reticulum (ER) where they are
released from the polyprotein by the action of the host signal
peptidase. This ER enzyme is oriented in the lumen and cleaves
the Core-E1, E1-E2 and E2-p7 junctions [8,9]. In the ER, HCV
envelope proteins acquire 4-5 and 11 N-linked glycosylation
chains for E1 and E2, respectively, and remain anchored to the
membrane through their hydrophobic C-terminal domains. It has
been reported that these transmembrane regions carry crucial
determinants for ER retention and E1E2 heterodimerization [10].
Formation of the heterodimer is a slow process that requires up to
6 hours to be completed [8,11].
A substantial number of reports have analyzed the folding/
assembly of HCV structural proteins and, in particular, individ-
ually expressed E2. There are several reasons for the increased
interest in the E2 glycoprotein. Firstly, E2 directly contacts host
membrane proteins required for virus entry, including CD81 [12]
and SR-B1 to which direct binding has been proven with the
soluble E2 protein [13]. Secondly, E2 is the target for most of the
neutralizing antibodies generated in mice or isolated from HCV
infected patients [14,15]. Thirdly, individually expressed E2, as
well as truncated forms of this protein, have been found to
properly fold and generate epitopes recognized by conformational
antibodies [16]. Indeed, a truncated form of this protein, that is
soluble and easier to purify than the full-length protein, has also
been indicated as a vaccine candidate [17].
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of an anti-HCV prophylactic vaccine, recent trials suggest that the
administration of both HCV glycoproteins as a heterodimer is
needed [18,19]. The current view is that co-expression of E1 and
E2 is required for the folding/assembly of E2 in its native structure
(reviewed in [20]). A purified soluble truncated form of E1 was also
investigated as a therapeutic vaccine in a pilot study, but no
significant reduction of HCV infection was observed [21]. Thus,
although the presence of anti-E1 neutralizing antibodies has been
described [22,23], formation of the heterodimeric complex seems
to be strictly required to generate an immunoprotective antigen.
Folding analysis of unescorted E1 has received less attention as it
was reported to be unable to fold properly when expressed in the
absence of E2 [16]. However, in a previous study we observed that
the oxidation process and the transient association with the ER
chaperone calnexin of individually expressed E1 proceeded as
expected for a correctly folded protein [24]. These data were
obtained using an in vitro translation system that did not allow us to
follow the fate of E1 at late time points post-synthesis. Thus,
although E1 appeared to reach a chaperon released conformation,
we could not analyze its stability as single expressed protein.
WesoughttoverifywhetherE1canachieveanativeconformation
in absence of E2 and generate a stable species to be purified and
tested for immunological protection. To overcome the limitation of
the in vitro system, in this study we analyzed the oxidative folding of
E1 individually expressed in stably transfected CHO cells and
compared the same process when the glycoprotein is expressed
together with E2 as a single coding unit. In CHO cells, the oxidation
and folding pathway of E1 is identical to the one observed for the
polyprotein, except for an acceleratedkinetics.The folding processof
individually expressed E2 (expressed as E2p7 precursor) was also
analyzed. In the absence of E1, only a low amount of properly
oxidized E2 could be seen suggesting that misfolding pathways
predominate in these conditions. However, both E1 and E2
expressed as single proteins were not stable in the cells and they
were cleared within a few hours after reaching a conformation that
was resistant to the reducing agent dithiothreitol (DTT).
Results
Experimental background
In this study we have used the structural region of the hepatitis C
virus Con1 strain (1b) for all the constructs [25] (EMBL database
accession number AJ238799). The coding regions corresponding to
E1E2p7, E1 and E2p7 have been amplified and cloned into an
eukaryotic expression vector. The E1 protein contains an additional
15aminoacidsC-terminusbelongingtotheN-terminussequence of
E2. The presence of this region is required to assure the correct
cleavage and glycosylation of E1, as reported previously [24]. These
constructs are shown in figure 1A. Constitutive expression of
E1E2p7, E1 and E2 in CHO has been achieved using stable
transfected cell lines standard procedure (detailed in Material and
Methods). The corresponding cell lines constitutively expressing
E1E2p7, E1 or E2p7 (CHO-E1E2p7, CHO-E1 and CHO-E2p7,
respectively) were screened by Western blot analysis and immuno-
precipitation following metabolic
35S-Met/Cys labeling (data not
shown). One clone of each construct was selected on the basis of the
amountandstabilityofexpressedproteinsafterseveralcell passages.
The folding kinetics of the products expressed by CHO-E1E2p7
was used as an internal controlto evaluate the foldingof E1 or E2p7
expressed alone in CHO cells.
We have previously shown that the chimpanzee antiserum Ch-
L559 was able to recognize all conformational species of E1 and
E2/E2p7 from strain HCV-1a [8,26]. Unfortunately this tool
failed to reveal HCV proteins from strain HCV-1b in immuno-
precipitation experiments, whereas it was still useful for Western
blot analysis of E2/E2p7. Thus, to perform our folding analysis we
have used human monoclonal antibodies generated from B-cells
isolated from HCV infected patients [27]. In particular, we
screened 9 anti-E2 monoclonal antibodies (mAb), five of which
recognized E2, with almost the same specificity. Among these
we selected the mAb CBH-7 that recognized a DTT-sensitive
conformational epitope of the E2 protein. Concerning E1, we used
the CBH-111 mAb that recognizes both reduced and oxidized
forms of E1 [22]. This antibody binds a conserved linear epitope
close to the N-terminus of E1 but, in our hands, does not lead to
E2 co-immunoprecipitation.
Oxidative kinetics is visualized by SDS-PAGE electrophoretic
mobility differences of partially or fully oxidized proteins under
non-reducing conditions, compared to the identical sample
migrated in reducing conditions [28]. We will refer to samples
as i) reduced proteins (red) for those in which DTT has been
added immediately prior to electrophoretic analysis, ii) oxidized
(ox) species for those that migrates faster than the reduced
counterpart and iii) unoxidized (unox) for those that display
slower migrating species in non-reducing conditions, whose intra-
chain disulfide bonds are variable.
EndoH digestion
Our aim was to study the folding capability and stability of
HCV glycoproteins expressed alone in eukaryotic cells. In
particular we meant to focus on the E1 protein considering that
this topic has been poorly addressed especially in the absence of
the other major HCV glycoprotein E2.
As a first step, we performed an Endoglycosidase H (EndoH)
digestion to establish whether unescorted E1 was retained in the ER.
This enzyme hydrolyzes high mannose N-linked chains resident in
the ER but it does not act on carbohydrate structures further
modified in the Golgi. The EndoH sensitivity of the sugar moiety of
glycoproteins represents an easy way to distinguish between ER-
localized proteins and species that have entered the anterograde
trafficking pathway. EndoH digestion analysisof protein expressed by
the E1 and E2p7 constructs compared with the control E1E2p7 was
performed at 20 min and 4 hrs chase-points.
The top panel of figure 1B shows the result of the analysis
performed on CHO-E1 and CHO-E1E2p7 cells. In both samples
the behavior of the E1 glycoprotein was identical at both times
post-synthesis. On the contrary, as shown in the bottom panel of
figure 1B, two major differences were revealed for E2 expressed
alone, with respect to the control: i) the relative amount of E2 and
E2p7 species and ii) the faster migration of deglycosylated E2/
E2p7 in CHO-E2p7 cells with respect to the control sample (lanes
6 and 8). Following deglycosylation, E2 and E2p7 were clearly
separated on the gel and, for products expressed by CHO-
E1E2p7, the cleavage of the precursor was time dependent (lanes 2
and 4). Indeed, comparing the relative intensity of E2 and E2p7
bands from CHO-E2p7 cells, revealed that the amount of mature
E2 did not substantially change between 20 min and 4 hours of
chase (lane 6 and 8). In the E2p7 sample we did not observe the
progressive maturation of the E2p7 precursor since the percentage
of the precursor appeared to be roughly equal irrespective of the
chase-time. Concerning the faster migration of the deglycosylated
E2 and E2p7 observed in CHO-E2p7 cells, the most likely
explanation would be a further proteolytic cleavage at the N-
terminal of E2 expressed singularly, but we did not investigate this
possibility further.
In conclusion, our data show that E1 expressed alone is
correctly matured by the signal peptidase and subjected to proper
Folding of Individually Expressed E1
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expressed in CHO-E2p7 cells shows remarkable differences
compared with the same species from CHO-E1E2p7 cells.
Oxidative kinetics
Pulse-chase experiments from 20 min to 4 hrs were performed to
study the oxidation kinetics of E1 and E2/E2p7 in stably transfected
CHO cells. The pulse-chased post-nuclear supernatants (PNSs) from
CHO-E1E2p7, CHO-E1 and CHO-E2p7 cells were subjected to
immunoprecipitation, SDS-PAGE analysis and autoradiography.
Results from representative gels are shown in figure 2. Panel A shows
the oxidative kinetics of E1 synthesized in the presence of E2 (left) or
in its absence (right). The time-dependent oxidation of E1 was
followed and quantified by the appearance of its faster migrating
band (ox- in the figure). As expected, the relative intensity of this band
increased over time until reaching a plateau. This process is common
to both constructs but with different kinetics. To better visualize such
differences, on the bottom of figure 2A a densitometric analysis of the
gels for each chase-time is shown, reporting the intensity of either the
oxidized or unoxidized forms expressed as a relative percentage. The
E1 protein from CHO-E1E2p7 cells showed a half-time (t1/2)o f
oxidation of about 80 min, still increasing after 4 hrs post-synthesis.
In contrast, E1 expressed alone oxidized faster, with a t1/2 value of
about 45 min, reaching the plateau within 3 hrs of chase.
Infigure2Barepresentativeexperimentoftheanalogousoxidative
analysis of CHO-E2p7 compared to the control CHO-E1E2p7
cell line is shown. Since the anti-E2 CBH-7 antibody used for the
immunoprecipitations recognizes only conformational epitopes, the
unoxidized forms of E2 and E2p7 were not present on the gel. While
this limitation does not allow a detailed analysis, such as densitometry
of the different species, the significant features of the oxidation
pathway of E2/E2p7 expressed individually can still be observed. E2
Figure 1. Endoglycosidase H sensitivity of HCV glycoproteins E1 and E2p7. (A) Recombinant constructs for E1, E2p7 and E1E2p7 expression
in CHO cells. Sequences coding for the structural protein E1 (aa. 165–398), E2p7 (aa. 365–809) and E1E2p7 (aa. 165–809) were amplified from a
replicon containing the entire HCV genome of HCV genotype 1b, subtype ConI as described in the Materials and Methods. These constructs were
used to stably express the proteins in CHO cells. Black segments represent the E1 (aa. 165–191) and E2 (aa. 366–384) signal sequences. The N-
terminus 15 amino acids of the E2 protein are shown as a dashed segment in the E1 construct. (B) CHO cells expressing E1, E2p7 or E1E2p7 were
pulse-labeled with [
35S]-methionine and -cysteine for 20 min and chased for the indicated time periods. PNSs were immunoprecipitated with an anti-
E1 (top panel) or anti-E2 antibody (lower panel) and further treated with (+) or without (2) EndoH. Proteins were separated on 10% SDS-PAGE in
reducing conditions. Asterisks indicate non-specific bands. E1DGly indicates the E1 protein co-immunoprecipitated with the anti-E2 antibody and
subsequentlydeglycosylated by EndoH treatment.
doi:10.1371/journal.pone.0023838.g001
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the 4 hrs chase-period (figure 2B, left panel). In contrast, E2
expressed in the absence of E1 revealed a less pronounced shift
between non-reduced and reduced samples, as well asfaster oxidative
kinetics reaching the plateau within 1 hr post-synthesis (figure 2B,
right panel. The position of the band in lane 3, 4 and 5 does not
change. And the intensity of the bands is better resolved in reducing
conditions,lanes 6–10). Preliminary conclusions from this analysis are
consistent with an accelerated but regular oxidation pathway for E1
in absence of the major HCV glycoprotein. However, E2/E2p7
oxidation appeared to be severely impaired.
DTT-resistance analysis
Proteins stabilized by intra-chain disulfide bonds are usually
resistant to reducing agents when they reach native conformation.
On the contrary, folding intermediates are fully or partially
susceptible to such chemicals [28]. This property is useful to judge
the oxidation status of a conformer. By adding an exogenous
reducing agent to a mixed population of folding protein, the native
species does not modify its migration pattern on a non-reducing
SDS-PAGE. On the other hand, folding intermediates will be
partially or fully reduced, migrating substantially slower in the
same electrophoretic conditions. Figure 3 shows a representative
experiment of DTT resistance of CHO-E1E2p7, CHO-E1 and
CHO-E2p7 cell lines. The antibodies used for immunoprecipita-
tion were anti-E1 CBH-111 (figure 3A) and anti-E2 CBH-7
(figure 3B).
Fig. 3A shows the pattern of E1 sensitivity to the exogenously
added reducing agent, both expressed in presence (left) or absence
(right) of E2. This parameter was evaluated on the basis of SDS-
PAGE migration in non-reducing conditions by comparing
samples derived from untreated and DTT-treated cells. Quanti-
Figure 2. Oxidation kinetics of E1 and E2p7 HCV glycoprotein. CHO cells stably transfected with constructs expressing E1, E2p7 or E1E2p7
were pulse-labeled with [
35S]-methionine and -cysteine for 20 min and chased for the indicated time-periods. PNSs were immunoprecipitated with
(A) CBH-111 anti-E1 monoclonal antibody or (B) CBH-7 anti-E2 monoclonal antibody. Samples were analyzed on 10% SDS-PAGE in non-reducing
(lanes 1–5) and reducing (lanes 6–10) conditions. For E1, the relative intensity of the unoxidized (grey bars) and oxidized (black bars) forms were
quantified for the different chase-times. The E1E2p7 wild type species is reported on the left graph, E1 alone on the right graph. The half-time (t1/2)o f
E1 oxidation represents the chase-time at which half of the protein is in its oxidized form. Symbols refer to: ox for oxidized; unox for unoxidized; red
for reduced.
doi:10.1371/journal.pone.0023838.g002
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these two conditions is reported in the graphics at the bottom of
figure 3A. This representation allows a direct comparison of the
behavior of the glycoprotein expressed by the two constructs. Both
in absence and in presence of E2, the amount of DTT-resistant
species increased over the entire chase-period. Individually
expressed E1 shows an accelerated oxidation pathway, consistent
with the kinetics shown in figure 2, while the kinetics of the DTT-
resistant conformation appeared similar between the two samples
(figure 3A). Indeed, at the end of the chase-period, the percentage
of the DTT-resistant conformer relative to the total E1 was
comparable among the two constructs (graphic in figure 3A). This
result suggests that E1 acquires a tighter conformation indepen-
dently of E2 co-expression.
Once again, substantial differences in the E2 DTT resistance
pathway have been revealed by analysis of E2 expressed alone, as
shown in figure 3B. To be able to compare different samples, we
normalized the PNSs submitted to immunoprecipitation. This
procedure was necessary since the anti-E2 antibody used in this
study did not recognize unoxidized forms of the protein, thus a
densitometric analysis on the two conformers (ox versus unox) of the
same protein could not be performed. To assess the percentage of
E2 that acquired DTT-resistance, following cell lysis and pre-
clearing of the PNSs, an equivalent amount of radiolabeled
proteins (measured as TCA insoluble radioactive fraction) were
submitted to immunoprecipitation [8]. The amount of the DTT-
resistant fraction could therefore be estimated from the total
immunoprecipitated pool by comparing the intensity of the bands
obtained in the presence and absence of exogenously added DTT.
A representative experiment of DTT-resistance by E2/E2p7
expressed in CHO-E1E2p7 cells is shown in the left panel of
figure 3B. It can be observed that both the oxidized (lanes 1, 3, 5
and 7) and DTT-resistant (lanes 2, 4, 6 and 8) E2 species increased
over time, but did not reach a plateau within the 4 hours of chase.
On the other hand, E2/E2p7 expressed in the absence of E1
(figure 3B, right panel) showed an increased amount of the DTT
resistant species within 1 hr of chase (compare lanes 2 and 4) that
did not rise further over the 4 hrs chase-period (lane 4 compared
to 6, 8 and 10). Thus, oxidation and achievement of a DTT
resistant conformation by E2/E2p7 expressed alone was faster but
much less efficient than when expressed together with E1.
Taken together these experiments confirmed that the achieve-
ment of E1 fully oxidized conformation is independent of the
presence of E2, whereas the requirement of E2 for its glycoprotein
partner is crucial for its correct oxidative folding.
HCV glycoprotein stability in CHO-E1E2p7, CHO-E1 and
CHO-E2p7
Recombinant HCV glycoproteins synthesized in stably trans-
fected eukaryotic cells are quite stable products that, once
associated as native heterodimers, accumulate in the cells. The
experiments described in the above paragraphs suggested that E1
Figure 3. Analysis of DTT-resistance of HCV proteins E1 and E2. (A) CHO cells stably transfected with E1E2p7 or E1 were pulse-labeled with
[
35S]-methionine and –cysteine for 20 min and chased for different time-periods in the presence (+) or absence (2) of 5 mM DTT added exogenously
5 min before the indicated chase-time. PNSs were immunoprecipitated with the CBH-111 anti-E1 antibody and samples analyzed on 10% SDS-PAGE
in non-reducing (lanes 1–10) and reducing (lanes 11–20) conditions. Graphs below represent the percentage of oxidized E1 present in samples
derived from untreated (black bars) and DTT-treated (dashed bars) cells. The relative intensity-percentage is calculated by densitometric analysis of
the unoxidized and oxidized forms in non-reducing conditions in the presence (lanes 1, 3, 5, 7, 9) or absence (lanes 2, 4, 6, 8) of 5 mM DTT added
exogenously 5 min before the indicated chase-period. Left graph reports values obtained when expressed with E2p7, right graph when expressed
individually. (B) CHO cells stably transfected with E1E2p7 or E2p7 were pulse-labeled with [
35S]-methionine and –cysteine for 20 min and chased for
different time-periods in the presence (+) or absence (2) of 5 mM DTT added exogenously 5 min before the indicated chase-time. PNSs were
immunoprecipitated with CBH-7 anti-E2 antibody and samples analyzed on 10% SDS-PAGE in non-reducing (lanes 1–5) and reducing (lanes 6–10)
conditions. Symbols refer to: ox for oxidized; unox for unoxidized; red for reduced.
doi:10.1371/journal.pone.0023838.g003
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of the total E2 expressed alone reaches a fully oxidized and
supposedly native conformation. We sought to verify the stability
of individually expressed E1 and E2 in our system compared to the
stability of the same proteins expressed on a single coding unit. To
this aim we performed several experiments extending the chase-
period to 6 and 15 hrs. To be able to compare samples at different
chase-periods, we immunoprecipitated equivalent TCA insoluble
counts as described above. The left panel of figure 4A shows the
results obtained with cells transfected with the reference constructs
E1E2p7, the PNS of which was immunoprecipitated with the anti-
E2 CBH-7 mAb. The amount of E1E2 heterodimer decreased
from 6 to 15 hrs (lane 2 compared to lane 1) even though the two
bands remained clearly detectable. The middle panel shows E1
immunoprecipitated with the CBH-111 anti-E1 antibodies from
CHO-E1 PNS. Unequivocally, at the 15 hrs chase-period the E1
band disappeared almost completely (lane 6 or 8). Identical results
were obtained from analysis of E2p7 expressed alone and
immunoprecipitated with CBH-7, shown in the right panel. At
6 hours we observed the plateau of E2 accumulation but it was
completely cleared by 15 hrs post-synthesis (lanes 10 or 12). Post-
synthetic accumulation at 6 and 15 hours represents the two
chase-periods that better embody our results. After 6 hrs chase, in
fact, both proteins from all three constructs reached the maximum
amount (data not shown). Similarly, we choose 15 hrs chase-time
since intermediate chase-periods resulted in variable percentages
of degradation. These data strongly indicate that both HCV
glycoproteins, when expressed as isolated subunits, are not stable
inside the cells.
The next experiment was designed to establish whether the
proteasome was implicated in E1 and E2/E2p7 degradation.
However, we could not use direct proteasome inhibitors, such as
lacticystin or MG132, since prolonged incubation with these
compounds led to extensive cell death. To overcome this problem
we used kifunesine, an ER mannosidase I inhibitor [29]. Misfolded
glycoproteins targeted for degradation need to be retro-translocated
into the cytosol, a process that requires recognition of the
oligosaccharide moiety by a specific family of receptors named
EDEM [30,31]. The EDEM substrate is generated by the action of
the ER mannosidase I, a slow acting enzyme which selectively
removes a single a-mannose from the core-glycan of glycoproteins
unable to escape the ER quality control machinery [32]. Thus,
inhibition of mannosidase activity acts upstream of proteasome
degradation by blocking the access route to the cytosol where the
ubiquitin-proteasome system is localized.
CHO-E1, CHO-E2p7 and CHO-E1E2p7 cells were pre-
incubated for 30 min with kifunesine, which was also maintained
in the culture media during pulse and the 6 and 15 hr chase-time.
At the end of these periods, cells lysates were immunoprecipitated
and HCV E1 and E2 proteins analyzed on SDS-PAGE. The
results from this experiment are shown in figure 4B. In the CHO-
E1E2p7 control sample, E1 and E2 bands are still present in a
significant amount in absence of kifunesine with a small increase in
the presence of the drug (lanes 1 and 7 compared to lanes 2 and 8).
The apparent MW of both proteins is shifted higher in the drug-
treated samples, as expected after the inhibition of trimming of
high mannose structures. E1 and E2 from CHO-E1 and CHO-
E2p7 lysates, respectively, are detectable at a low amount in
samples derived from kifunesine treated cells (lanes 4, 10 and 6,
12). Thus, the presence of the inhibitor is able to trigger a certain
degree of protection from degradation. This result is consistent
with the quick degradation of E1 and E2 when they are not
co-expressed and is consistent with the involvement of the
proteasomal pathway in the clearance of the HCV glycoproteins.
Discussion
During infection of host cells by enveloped virus, the fusion of
the viral envelope and the cellular membrane is facilitated by
viral fusion proteins. The fusion mechanism shares common
features in all viral families so far described, but the overall
structure of the different fusion proteins evolved separately and
they are characterized as three distinct classes [33]. Fusion
proteins of the Togaviridae and Flaviviridae families belong to the
class II [34,35], which most likely also contains the E2 protein of
HCV [36]. Class II fusion proteins share a common molecular
architecture and need a ‘‘partner’’ subunit with which they fold
and form heterodimers. The chaperone-like role of this second
protein, whose synthesis precedes that of the class II proteins, has
been demonstrated for Semliki Forest virus (SFV) and tick-borne
encephalitis viruses (TBE) [37,38]. Another aspect shared by
these chaperone-like subunits is their ability to fold correctly once
expressed individually. Indeed, both the p62 protein of SFV and
the prM protein of TBE did not show any major difference in
folding once expressed in the absence of the second subunit on
the coding unit [37,38]. Differently from both SFV p62 and TBE
prM proteins, however, E1 does not undergo proteolytic
processing prior to virus release. Furthermore, the resulted
HCV infectious particles are resistant to acidic pH treatment
[39]. These data may suggest a different role of E1 during entry
or fusion steps.
Previous data generated in our laboratory suggest that the HCV
glycoprotein E1 could play a role analogous to p62 and PrM in
viral maturation. In an in vitro translation system, unescorted E1
was able to achieve a complete folding process once provided with
a small region of E2 that ensured the correct topology of the C-
terminus [24]. Afterwards, folding/assembly analysis of E1E2
stably expressed in eukaryotic cells revealed that E1 oxidation
preceded E2 maturation, a behavior consistent with a potential
chaperone-like role for the E1 protein [8]. The analysis performed
here extends these previous reports by analyzing the mechanism of
unescorted E1 folding in stable transfected CHO cells and its
stability at longer time points post-synthesis. The folding pathways
of individually expressed E2, and E1E2 as single coding unit, were
evaluated in the same system.
In terms of its general features, the individually expressed E1
was indistinguishable from the E1 expressed in the control
expression unit: it did not present high molecular weight
aggregates, it received the proper number of carbohydrates chains
and was retained in the ER. The oxidative kinetics of E1 expressed
as a single protein showed a complete oxidation between 2 and 3
hours post-synthesis (t1/2= ,45 min). This kinetics was slowed
down by the presence of E2, requiring up to 4 hrs to be completed
(t1/2= ,80 min). This result is consistent with a chaperone-like
role played by E2 whose co-expression delays folding kinetics.
However, the establishment of a DTT-resistant conformation for
the E1 protein was a slow process proceeding independently of the
presence or absence of E2 and it required approximately 4 hours
to be achieved. Indeed, the percentage of the DTT resistant
species was roughly equivalent in the two samples, without any
yield increase of fully oxidized E1 when co-expressed with E2. Our
folding analysis was also extended to detect association of E1 with
ER resident chaperones, however we were not able to identify
these in our system. In particular, we were unable to reveal any
transient association with ER chaperones and calnexin (data not
shown). This observation was particularly surprising since in a
previous study we were able to detect a transient association of this
lectin-type chaperone with E1 expressed as the polyprotein [8]. It
could be possible that the accelerated oxidation of unescorted E1
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interaction is so accelerated that it is difficult to detect.
Although our primary focus was E1, we performed parallel
analysis of individually expressed E2 folding. To this end, we used
a series of monoclonal conformational antibodies that limited our
study to the detection of partial or fully folded protein. In our
hands, the oxidation pathway of individually expressed E2 was
severely impaired as was the achievement of a DTT-resistant
Figure 4. E1 and E2 stability in CHO stably trasfected cells. (A) CHO cells expressing E1, E2p7 or E1E2p7 were pulse-labeled with [
35S]-
methionine and –cysteine for 20 min and chased for 6 and 15 hrs. PNSs were immunoprecipitated with the CBH-111 anti-E1 monoclonal antibody
(central panel) or the CBH-7 anti-E2 monoclonal antibody (lateral panels). Samples were analyzed on 10% SDS-PAGE in non-reducing (lanes 1, 2, 5, 6,
9, 10) or reducing (lanes 3, 4, 7, 8, 11, 12) conditions. (B) CHO cells stably transfected with E1, E2p7 or E1E2p7 were pulse-labeled with [
35S]-
methionine and –cysteine for 20 min and 15 hrs. During the pulse- and chase-time, the medium was supplemented with (+) or without (2)2 0mM
kifunesine. PNSs were immunoprecipitated with the CBH-111 anti-E1 antibody (lanes 3, 4 and 9, 10) or the CBH-7 anti-E2 monoclonal antibody (lanes
1, 2, 5, 6, 7, 8, 11, 12). Samples were analyzed on 10% SDS-PAGE in non-reducing (lanes 1–6) or reducing (lanes 7–12) conditions.
doi:10.1371/journal.pone.0023838.g004
Folding of Individually Expressed E1
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23838conformation. These observations confirm previous studies
showing the requirement of E1 co-expression and are consistent
with a chaperone-like role of E1 [8,40]. Recent work from Krey et
al. further supports our conclusion on the relative role of E1 and
E2 on their own folding [36]. These authors obtained very
interesting findings on the overall E2 structure by analysis of a
purified soluble truncated form of E2 whose folding was assisted by
co-expression of the full length E1.
The finding that individually expressed E1 was able to
successfully achieve a complete folding pathway is consistent with
assessed data on analogous proteins from related viruses, namely
TBE preM or p62 from SFV. However, such proteins have been
followed only for the time required to complete folding, which is
60 and 15 min post-synthesis, respectively [37,38]. Our analysis,
however, was extended to determine the stability of unescorted E1
inside the cell. This study revealed that the persistence of
intracellular E1 was linked to the contemporary presence of E2,
likely associated in a heterodimer. Since inhibition of mannose
trimming stabilizes the substrate protein that is targeted for
degradation, the recovery of a low amount of E1 in overnight
kifunesine-treated cells suggests that endoplasmic reticulum
associated degradation (ERAD), with the proteasome as a final
destination, are involved in this clearing [41,42]. Contrary to what
was observed for the E1 folding process, E2 does play a role in
stabilizing the native E1 conformation.
Overall, E1 and E2 appear to assist each other but via two
different strategies. E1 is required for a correct oxidation pathway
of E2, slowing down the oxidative kinetics, increasing yield and
preventing aggregation for the time required to install productive
intra-chain interactions and reshuffling of disulfide bonds. With
respect to this aspect, E1 has a similar mechanism of action to that
of chaperones belonging to the Hsp70 or the lectin-like family
[43,44]. On the other hands, E2 also slows down oxidation of E1
but it does not appear to interfere with the achievement of the
mature conformation of E1 while protecting this molecule from
cellular degradation. This behavior mimics the action of species
belonging to the Hsp90 family that induce conformational changes
of native species leading to their activation or stabilization [45].
According to these conclusions, E2 would always require E1 co-
expression in cis, whereas a portion of E2 might be sufficient to
stabilize full length E1 in a native conformation.
E2 carries the major antigenic epitopes and, for obvious
reasons, it has been targeted as the most promising candidate for
the development of a protective vaccine [18]. E1 is the less studied
molecule of the pair even though it could be an attractive vaccine
candidate, in terms of sequence conservation, absence of
hypervariable regions and the presence of monoclonal neutralizing
anti-E1 antibodies [22,23]. We believe that this report provides the
experimental basis for generating a stable E1 molecule to be
purified and investigated for its immunogenic properties.
Materials and Methods
Antibodies and reagents
The anti-E2 mAb CBH-7, which recognizes a conformational
epitope of E2, and the anti-E1 mAb CBH-111, which recognizes a
linear epitope of E1, have been previously described [22,27].
Endoglycosidase H, complete protease inhibitor EDTA-free
tablets, PMSF, NEM and DTT were purchased from Roche;
kifunesine was purchased from Sigma-Aldrich.
Generation of stably transfected cells
A replicon containing the entire genome of HCV genotype 1b,
subtype ConI was isolated as previously described [25]. Sequences
coding for HCV structural proteins E1 (aa. 165–398), E2p7 (aa.
365–809) and E1E2p7 (aa. 165–809) were amplified from the
replicon. Primers used for amplification are:
for E1 59 CGGCGTCGACATGGCAACAGGGAAT-
CTGCCCGG 39
59 GGCCAAAAACACCCTCGGGTAAGAAT-
TCTTTT 39
for E2p7 59 CTACGTCGACATGGGGGAACTGGGC-
TAAGG 39
59 CCACGAGCATACGCCTAAGAATTCT-
TTT 39
for E1E2p7 59 CGGCGTCGACATGGCAACAGGGAAT-
CTGCCCGG 39
59 GGCCAAAAACACCCTCGGGTAAGAA-
TTCTTTT 39
Amplified fragments were digested with SalI and EcoRI
(New England Biolabs) and cloned into the pCMVIII vector
(Chiron corporation) carrying the genticin resistance gene and the
dihydrofolate reductase (DHFR) gene under control of an EMCV
promoter. The sequences of the inserts were verified by sequencing.
In these constructs, all proteins are targeted to the endoplasmic
reticulum by their own signal sequence. For our experiments, an
E2p7 constructs including a shorter signal sequence (365–383
instead of 352–383) was chosen since, from preliminary experi-
ments, it was found equally efficient in targeting E2p7 to the ER
while an increased cellular expression level was obtained in stable
transfected cells.
A DHFR-deficientChinese Hamster Ovary (CHO, clone DG44)
cells were transfected with constructs expressing E1 (CHO-E1),
E2p7 (CHO-E2p7) or E1E2p7 (CHO-E1E2p7), and selected for
stable clones as described previously [46]. Screening of HCV
proteins expressing clones was performed by Western blot for the
presence of recombinant proteins. Cells expressing E1, E2p7 or
E1E2p7 were further expanded and grown in a-MEM without
nucleoside and ribonucleosides, supplemented with 10% dialyzed
fetal bovine serum (dFBS, Gibco-Invitrogen), 1 mM L-glutamine,
0.02% proline and antibiotics, 100 mM geneticin (G-418, Gibco-
Invitrogen) at 37uC with 5% CO2.
Untransfected cells were grown in F12 (Gibco-Invitrogen)
supplemented with 10% dFBS, 1 mM L-glutamine, 0.02% proline
and antibiotics, at 37uC with 5% CO2.
Cell labeling and pulse-chase analysis
Metabolic labeling was performed by adding 100–200 mCi/ml of
[
35S]-labeled cysteine and methionine (ProMix, Amersham Phar-
macia Biotech) to cell medium and incubating for 6 or more hrs at
37uC with 5% CO2. For pulse-chase experiments, subconfluent
CHO-E1, CHO-E2p7 and CHO-E1E2p7 cells grown in 60 mm
diameter dishes (Falcon) were starved for 90 min in cysteine- and
methionine-free a-MEM (starving medium). Cells were then pulsed
supplementing the cysteine- and methionine-free medium with
800 mCi/ml of [
35S]-labeled cysteine and methionine (ProMix,
Amersham Pharmacia Biotech) for 20 min. After washingcells once
with starving medium, the chase-period was started by adding a-
MEM supplemented with 25 mM unlabeled cysteine and methio-
nine. For DTT resistance experiments, the chase-time was followed
by 5 min incubation in presence of 5 mM DTT added to the
medium. Experiments with the ER mannosidase inhibitor were
performed by supplementing culture medium with 20 mM kifune-
sine during pulse- and chase-time.
At the end of each chase-time, cells were placed on ice for 5 min
in cold PBS containing 1 mM PMSF and 20 mM NEM. After
removal of cold PBS, 1 ml of lysis buffer (50 mM Hepes pH 6.8,
200 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM PMSF,
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added to each plate and cells were removed using a cell scraper.
The suspensions were then transferred to a 1.5 ml eppendorf tube
and incubated for 30 minutes at 4uC on a rotating wheel. Total
lysates were centrifuged for 30 min at 16000 x g at 4uC. Post-
nuclear supernatants (PNSs) were used for immunoprecipitation
experiments.
Immunoprecipitation, SDS-PAGE and DTT-resistance
analysis
PNSs were precleared with protein G and protein A coupled to
Sepharose Fast Flow (Amersham Pharmacia Biotech) for 1 hr at
4uC. When specified, we determined the fraction of labeled amino
acids incorporated into proteins by thricholroacetic (TCA)
precipitation procedure. Briefly, 2 ml of each precleared lysate
(triplicates) were added to 200 ml of 20% cold thrichloroacetic
acid, mixed and placed on ice for 10 min to allow precipitation of
high molecular weight molecules. Each precipitate was collected
via vacuum filtration through a Whatmann GF/C glass fiber filter
prewetted with 5% TCA. After three washes of the tube with cold
5% TCA passed through the filter, dryed filters were placed in
scintillation vials to which 2 ml of aqueous scintillation cocktail
were added and count in a scintillation counter. The cpm obtained
reflect the amount of radioactivity that was incorporated into
proteins. Equivalent amounts of total labeled proteins were used
for immunoprecipitations. Immunoprecipitations were carried out
overnight with 0.5 mg CBH-7 and 0.5 mg CBH-111 at 4uCi n
presence of 6 ml of Dynabeads Protein G (Dynal Biotech ASA).
The beads containing the immunoprecipitated proteins were
collected with a magnetic support (Biorad) and washed 3 times
with cold lysis buffer containing 0.5% Triton. Elution of the
proteins from the beads was performed with SDS loading buffer at
95uC for 5 min. Samples were then analyzed by SDS-PAGE,
followed by autoradiography (Storage Phosphor Screen, Amer-
sham). For SDS-PAGE in reducing condition, a final concentra-
tion of 250 mM DTT was added to the samples.
For DTT-resistance analysis, duplicate plates were prepared for
each sample. At each chase-time, 5 mM DTT was added in the
culture medium to one plate of the pair 5 min before the end of
the chase-period. Following cell lysis and immunoprecipitation,
SDS-PAGE analysis was then performed in both non-reducing
and reducing conditions.
Endoglycosidase digestion
Endoglycosidase H digestions were performed on aliquots
(10 ml) of immunoprecipitated proteins recovered from the beads
in SDS loading buffer. To quench the SDS, samples were added to
200 ml (20 times v/v) of EndoH buffer (125 mM Sodium Acetate
pH 5.8, 250 mM b-mercaptoethanol, 5 mM PMSF) containing
1% triton X-100. After warming at 95uC for 3 min, samples were
allowed to reach room temperature and incubated with 10 mU
endoglycosidase H. The reactions were performed at 37uC
overnight. Digested proteins were precipitated in TCA and
resuspended in loading buffer with 250 mM DTT for SDS-PAGE
analysis.
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